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Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of
Glasgow, Glasgow, United Kingdoma; Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne,
Parkville, Victoria, Australiab; Centre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, University of
Edinburgh, Edinburgh, United Kingdomc; Glasgow Polyomics, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdomd
In vitro culture methods underpin many experimental approaches to biology and drug discovery. The modification of estab-
lished cell culture methods to make themmore biologically relevant or to optimize growth is traditionally a laborious task.
Emerging metabolomic technology enables the rapid evaluation of intra- and extracellular metabolites and can be applied to the
rational development of cell culture media. In this study, untargeted semiquantitative and targeted quantitative metabolomic
analyses of fresh and spent media revealed the major nutritional requirements for the growth of bloodstream form Trypanosoma
brucei. The standard culture medium (HMI11) contained unnecessarily high concentrations of 32 nutrients that were subse-
quently removed to make the concentrations more closely resemble those normally found in blood. Our newmedium, Creek’s
minimal medium (CMM), supports in vitro growth equivalent to that in HMI11 and causes no significant perturbation of me-
tabolite levels for 94% of the detected metabolome (<3-fold change; 0.05). Importantly, improved sensitivity was observed
for drug activity studies in whole-cell phenotypic screenings and in the metabolomic mode of action assays. Four-hundred-fold
50% inhibitory concentration decreases were observed for pentamidine andmethotrexate, suggesting inhibition of activity by
nutrients present in HMI11. CMM is suitable for routine cell culture and offers important advantages for metabolomic studies
and drug activity screening.
Trypanosoma brucei is the kinetoplastid parasite responsible forhuman African trypanosomiasis (HAT), a potentially fatal in-
fection of sub-Saharan Africa. Current treatments for HAT are
inadequate because of high toxicity and complex administration
regimens, and new drugs are urgently required to ensure ongoing
control of the disease in the face of emerging reports of drug re-
sistance (1). Newly invigorated efforts to bring novel compounds
forward as drugs have led to several promising candidates emerg-
ing through screening against parasites in culture (2–5). In vitro
continuous culture methods enable the routine screening of com-
pounds for trypanocidal activity against bloodstream form try-
panosomes, for example, with resazurin fluorescence-based assays
(5–7).
Culture methods for bloodstream form T. brucei were first de-
veloped in the 1970s and required feeder layers to support contin-
uous growth (8). This requirement could be overcome by regular
supplementation with cysteine (9) and supplementation with
mammalian serum (10). Continuous culture was successfully
maintained by the addition of reducing and chelating agents (2-
mercaptoethanol and bathocuproine sulfonate) to modified
Iscove medium with 10% fetal bovine serum (HMI11) (11). HMI11
is now widely used for routine cell culture of laboratory strains of
T. brucei and underpins many of the approaches employed in the
search for new trypanocidal compounds. Nevertheless, HMI11 is
a very rich medium compared to the natural in vivo environment
of bloodstream formT. brucei, which may give rise to biochemical
or pharmacological activities that are not relevant in vivo.
Metabolomics enables the simultaneous measurement of
many metabolites in any system and offers great promise for phar-
macological research (12–14). Metabolomic applications are rap-
idly expanding in the field of postgenomic biology, and it has
recently been demonstrated as an untargeted method allowing the
determination of mechanisms of drug action (15, 16). Mechanis-
tic knowledge of drug action should allow the rational optimiza-
tion of trypanocidal compounds to develop new drugs based on
either existing drugs or novel chemotypes identified through
high-throughput screening. While the availability of in vitro cul-
ture methods for T. brucei enables relatively simple evaluation of
drug-induced changes in the parasite metabolome, the use of a
rich medium (HMI11) raises some practical limitations. Primar-
ily, the high concentration of 35 common metabolites in HMI11
makes it difficult to observe metabolic alterations involving these
metabolites. This occurs because relative changes are much less
pronounced when there is a large background metabolite pool
present and absolute analytical error margins tend to increase
along with metabolite intensities. Also, drug-induced metabolic
perturbations can be easily masked by compensatory mechanisms
if there are high metabolite concentrations available in the culture
medium. This issue is not limited to drug-induced perturbations,
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as studies of genetic manipulation for target validation may also be
complicated by excess nutrient availability (17). Indeed, this “me-
tabolite rescue” approach is often used intentionally to generate
conditional gene knockouts or to confirm chemical or genetic
enzyme inhibition (17, 18). However, the use of a rich culture
medium may unintentionally hinder drug discovery efforts that
utilize phenotypic screening approaches, as demonstrated for di-
hydrofolate reductase (DHFR)-thymidylate synthase inhibitors,
which demonstrated significant trypanocidal activity only when
the medium was depleted of folic acid (17). The same type of
masking where highly abundant culture medium components
compete with drugs for targets or transporters will also influence
screening for other antimetabolites. The ideal culture medium
would be one that supports optimal in vitro cell growth while also
resembling as closely as possible the in vivo environment of the
parasite.
The ability to quantify changes in metabolite levels in growth
medium with relative ease offers great potential for the rational
optimization of culture media (19, 20). Targeted metabolic pro-
filing approaches may be used to quantify nutrient utilization and
to allow comparison of metabolite levels to biologically relevant
concentrations. Untargeted metabolomics allows the observation
of all of the relative changes in metabolite concentrations in cul-
ture media during growth and may highlight a depletion of essen-
tial nutrients that would not have been analyzed by traditional
targeted approaches.
The aim of this study was to utilize metabolomic technology
for the rational development of a simple culture medium optimal
for in vitro continuous culture of bloodstream form T. brucei. The
improved medium contains biologically relevant concentrations
of essential nutrients and avoids supranutritional levels of metab-
olites that interfere with metabolomic experiments and standard
drug activity assays. The new medium was tested for performance
by phenotypic assessment, metabolomic analysis, and drug activ-
ity assays.
MATERIALS AND METHODS
Parasite culture.Bloodstream formT. brucei brucei (s427) was cultured in
vitro in HMI11 (Gibco) (11), Creek’s minimal medium (CMM) (Table 1),
or modified media as described later. All media contained 10% fetal calf
serum (FCS) Gold (PAA, Piscataway, NJ). Cell culture grade (or high-
purity) D-glucose, L-cysteine, and L-glutamine and all other medium com-
ponents were purchased from Sigma-Aldrich. Five-milliliter cultures were
maintained in 25-ml vented flasks (Corning) at 37°C with 5% CO2. Cul-
tures were grown to a maximum density of 4  106 cells ml1 and sub-
cultured by 1-in-100 or 1-in-1,000 dilution every 2 or 3 days, respectively.
Cell counts were obtained with a hemocytometer (Neubauer).
Untargeted metabolomic analysis. Metabolite extraction was per-
formed according to previously described methods (21, 22). A 25-ml vol-
ume of cell culture was quenched by rapid cooling to 4°C in a dry ice-
ethanol bath. Cell pellets were obtained by centrifugation at 1,250 g for
10 min, and 5 l of spent medium was removed and extracted by the
addition of 100 l chloroform-methanol-water (1:3:1). The remaining
cell pellet was washed with 1 ml of phosphate-buffered saline (PBS), and
the washed pellet (5 107 cells) was extracted with 100l of chloroform-
methanol-water (1:3:1) by mixing for 1 h at 4°C before centrifugation to
remove precipitate. The resulting metabolite solution was stored at
80°C until analysis by liquid chromatography-mass spectrometry (LC-
MS). Comparative data from HMI11 and CMM cell pellets and spent
medium are from five independent biological replicates.
LC-MS analysis utilized hydrophilic interaction chromatography with
a ZIC-HILIC column (Sequant) and a formic acid mobile phase and was
coupled to high-resolution MS with the Exactive Orbitrap (Thermo) op-
erating in both positive and negative modes with all parameters as previ-
ously described (23).
Metabolomic data analysis was performed with IDEOM (http:
//mzmatch.sourceforge.net/ideom.php). The IDEOM workflow includes
untargeted peak picking by XCMS (Centwave) (24), peak matching and
annotation by mzMatch (25), and noise filtering and metabolite identifi-
cation by IDEOM, with the default parameters (26). Metabolite identifi-
cation is based on accurate mass and predicted retention time, which is
accepted as a level 3 standard of identification by the Metabolomics Stan-
dards Initiative (MSI) (27) but should be considered a putative identifi-
cation. Retention time was verified by authentic standards for the major
HMI11 components and other metabolites where possible. These high-con-
fidence (MSI level 1) identifications are highlighted (yellow) in the IDEOM
files in the supplemental material; further information to assist with inter-
pretation of the confidence of putative identifications in the supplemental
material is available in the IDEOM help file (http://mzmatch.sourceforge
.net/ideom/Viewing_results_with_Ideom.pdf). Relative quantitation for
untargeted analysis is based on raw peak heights. Comparative analysis is
based on relative mean peak height, and statistical analyses used unpaired
rank product analysis (28). No normalization was applied to untargeted
data, although signal reproducibility was ensured by the routine analysis
of six spiked internal standards, median peak heights, total ion current
chromatograms, and technical replicates of pooled samples (quality con-
trols).
Targeted and semiquantitative metabolomic analyses. Targeted
quantitative and untargeted semiquantitative metabolomic analyses were
done by the same procedure as described for untargeted analysis, with the
addition of fully labeled Escherichia coli extract as an internal standard at a
1:4 ratio before the extraction step (29, 30). Fully labeled E. coli was gen-
erated by the incubation of E. coli MG1655 with 500 ml of M9 minimal
medium and 0.3% (wt/vol) [U-13C]glucose overnight. E. coli metabolites
were extracted when the culture reached an optical density at 600 nm of
1.0 by the addition of 8 ml of20°C acetonitrile-methanol-water (2:2:1)
to the cell pellet as previously described (31), and the extract was stored at
80°C until required.
Calibration curves for LC-MS quantification were generated for each
metabolite with serial dilutions of freshly prepared authentic standards in
TABLE 1 Recipe for CMM
Component Concna or amt
D-Glucose 10,000 (1,800)
L-Glutamine 1,000 (146)
L-Cysteine 1,000 (121)
NaCl 77,590 (4,500)
CaCl2 · 2H2O 1,490 (219)
KCl 4,400 (330)
MgSO4 · 7H2O 814 (200)
NaHCO3 35,950 (3,020)
HEPESb 25,032 (5,960)
Phenol red 42 (15)
Bathocuproinedisulfonic acid 52 (28)
Mercaptoethanolc 192, 15 l
Water 900 ml
NaOHd to bring pH to 7.4 As required
FCS Gold (PAA)e 10%, 100 ml
a Unless stated otherwise, all values are M (mg liter1) concentrations. All component
concentrations are from the HMI11 recipe (11), except those of D-glucose, L-glutamine,
and L-cysteine.
b HEPES can be decreased to 10 mM to improve LC-MS compatibility for metabolomic
experiments.
c Mercaptoethanol should be added under a fume hood.
d All components should be dissolved in water, pH adjusted, and sterile filtered.
e FCS should be added just prior to use.
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80 l of methanol-water (1:1) with 20 l of fully labeled E. coli extract.
LC-MS was performed as described for untargeted analysis. Data analysis
was performed with LC Quan (Thermo) to manually integrate peak areas,
which were normalized on the basis of the coeluting fully labeled analyte
from the E. coli extract. Where authentic standards were available, metab-
olite concentrations were calculated from calibration curves and cor-
rected for dilution. Where authentic standards were not available, semi-
quantification was performed in IDEOM (26), whereby the raw peak
height was normalized to a fully labeled internal standard; for metabolites
where no internal standard was detected, normalization was based on two
fully labeled internal standards with retention times nearest to that of the
metabolite.
Metabolomic analysis of drug action. Metabolomic analysis of drug
action was based on the general method previously described for trypano-
cidal drugs (15). Pentamidine death curves were obtained for various
doses and treatment durations by cell counts of cultures at a parasite
density that would provide a suitable biomass for metabolomic analysis
(2 106 cells ml1). Drug concentrations were selected that mediated an
approximately 20% reduction of parasitemia at 48 h. In order to obtain
equivalent parasite cultures for metabolomic sampling, a confluent cell
culture was subcultured into five flasks of fresh medium at 4  104 cells
ml1 and pentamidine was added to four flasks at set times in order to
obtain samples with 48, 24, 12, and 1 h of drug exposure (see Fig. S1 in the
supplemental material). All samples, including the untreated sample,
were extracted when they reached 2  106 cells ml1. As some growth
defect was observed in the 48-h treatment, an additional untreated control
was included that started with a lower cell density (2 104 cells ml1) and
reached the sampling density (2  106 cells ml1) after 48 h, therefore
being exposed to the culture medium for the same time as the samples
treated for 48 h. The 0-h control was spiked with pentamidine after me-
tabolism was quenched to 4°C, whereas the 48-h control remained drug
free, thus providing an implicit validation of the quenching method,
ensuring no ion suppression due to the pentamidine solution and
allowing the identification of peaks that arise from the pentamidine
solution itself. Four independent biological replicates were analyzed
for each time point in HMI11, and three replicates were analyzed for
each time point in CMM.
Drug activity screening.Methotrexate, curcumin, diminazene, meth-
ylene blue, 2-deoxyglucose, phloretin, and 5-fluorouracil were purchased
from Sigma-Aldrich; acivicin was from Biomol International; eflornithine
was a gift from Pere Simarro (World Health Organization); NA42 was a
gift from Boris Rodenko (University of Glasgow); nifurtimox was a gift
from Vanessa Yardley (London School of Hygiene and Tropical Medi-
cine); suramin was a gift from Mike Turner (University of Glasgow);
melarsen oxide was a gift from Alan Fairlamb (University of Dundee);
pentamidine was a gift from Pere Simarro (World Health Organization);
and DB75 was a gift from Rick Tidwell (University of North Carolina,
Chapel Hill).
The activities of trypanocidal compounds were tested in a serial drug
dilution assay in order to determine the IC50s (drug concentration causing
50% growth inhibition) with the alamarBlue assay (6). Briefly, 2-fold
serial dilutions of the test compounds were prepared in 96-well microtiter
plates containing either HMI11 or CMM. Bloodstream form T. brucei
parasites in the log phase of growth were diluted in HMI11 or CMM and
inoculated into each well to a final concentration of 1  104 cells ml1.
After 48 h of incubation at 37°C under a humidified 5% CO2 atmosphere,
20l of resazurin (12.5 mg of resazurin [Sigma-Aldrich] in 100 ml of PBS)
was added to each well and the cultures were incubated for an additional
24 h. Fluorescence detection was performed with a FLUOstar Optima
Microplate Fluorometer (BMG LABTECH GmbH) at excitation and
emission wavelengths of 530 and 590 nm, respectively. To assess cell sen-
sitivity to the trypanocides, data were log transformed and the IC50s were
determined by regression from the sigmoidal dose-inhibition curve with
GraphPad Prism. Three to nine biological replicates were carried out for
each of the trypanocidal compounds. Comparative statistics utilized the
unpaired Welch t test (  0.05).
RESULTS
Trypanosome nutrient utilization from standard growth me-
dium. In order to develop an optimal simplified growth medium,
it was first necessary to determine which nutrients are significantly
consumed by trypanosomes from standard HMI11 medium. Me-
dium samples were collected from fresh and spent HMI11 me-
dium after 56 h of growth during which the trypanosome density
increased from 2  104 to 4  106 cells ml1, which is the peak
density obtained in this medium. These samples were analyzed by
a high-resolution LC-MS metabolomic approach that combines
the targeted quantitative analysis of selected metabolites with the
untargeted semiquantitative analysis of all putative metabolites.
This analysis revealed minimal consumption of most nutrients
from the medium, although a 32% decrease in phenylalanine was
observed (Fig. 1A). Glucose and cysteine also decreased, although
absolute quantification of these metabolites by the HILIC-
Orbitrap is hindered because of relatively poor chromatography
of reducing sugars and oxidation of thiols during sample prepa-
ration and autosampler storage (22, 32). Nevertheless, it is well
established that bloodstream form trypanosomes in cell culture
utilize significant amounts of both glucose (33) and cysteine (34).
In addition to the defined components of HMI11, an untargeted
metabolomic analysis allowed investigation of the utilization of
serum-derived nutrients. While many nutrients were not affected
by cell growth, significant depletion of lysophosphatidylcholines
(LPCs) and the purine nucleosides inosine and guanosine was
observed (Fig. 1B). The nutrients that accumulated the most in
spent medium were pyruvate, the major end product of aerobic
glycolysis in T. brucei (33), and alanine, the aminated product of
pyruvate. Increased levels of several keto acids were also observed,
likely because of deamination of the amino acids phenylala-
nine, tryptophan, tyrosine, valine, (iso)leucine, methionine,
and glutamate.
Development ofminimal growthmedium.As the initial anal-
ysis indicated that no HMI11 components were consumed to ex-
haustion during a standard cell culture passage, altered HMI me-
dium was prepared containing 10% FCS, basal medium (salts,
buffers, and antioxidants), glucose, glutamine, and cysteine ac-
cording to the HMI11 formula and other components at a 10-fold
dilution. Two media were further derived from this by the omis-
sion of (i) vitamins or (ii) amino acids and nucleotide precursors.
Surprisingly, both media supported cell growth to the same degree
as HMI11 (Fig. 2A) and no major nutrient depletion was ob-
served, with the exception of phenylalanine and tryptophan. Final
medium optimization was performed with each combination of
cysteine, glutamine, phenylalanine, and tryptophan, in addition
to glucose and the basal medium. These experiments confirmed
that cysteine is essential for growth (34), along with either glu-
tamine or a combination of phenylalanine and tryptophan
(Fig. 2B). Therefore, the minimal nutrient combination required
for continuous in vitro culture was glucose, cysteine, and glu-
tamine. The concentrations of these three components were then
reduced to the final concentrations shown in Table 1 without af-
fecting the growth rate. Our optimal recipe (Table 1), referred to
as CMM, supports growth rates identical to those obtained with
HMI11 under standard cell culture conditions, and cells enter
stationary phase at a density similar to that of cells in HMI11
Creek et al.
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(Fig. 2). CMM supports normal growth when used for routine cell
culture (see Materials and Methods) up to at least 25 passages
(after which it was not tested because we routinely cull the cells
and begin a new stabilate at that point). All development work was
performed withT. brucei brucei strain WT427, and normal growth
of strain 2T1, which is commonly used in RNA interference work,
was also observed (35). Partial depletion of glutamine, phenylal-
anine, and tryptophan and accumulation of pyruvate and alanine
were observed in spent CMM following a 56-h passage up to a
density of 4 106 cells ml1 (Fig. 1A). No significant changes in
nutrient concentrations were observed in cell-free CMM controls
incubated at 37°C for 56 h. Limited testing of the long-term sta-
bility of this medium has been performed. Serum-free CMM is
effective for at least 6 months if stored at 4°C, supporting normal
growth after the addition of fresh serum. CMM containing 10%
FCS is able to support routine cell culture after storage at 4°C for at
least 2 months (data not shown).
Quantitative measurement of metabolite levels in fresh CMM
and HMI11 was done by LC-MS with stable-isotope-labeled in-
ternal standards. Interestingly, many of the components that were
excluded from the HMI11 recipe were still present in CMM
(Table 2), confirming that 10% FCS Gold provides an adequate
supply of most of the nutrients essential for trypanosome growth.
Importantly, the excessive concentrations of most HMI11 com-
ponents were avoided in CMM; for example, hypoxanthine and
nicotinamide levels in HMI11 are 200-fold higher than neces-
sary. Average metabolite concentrations in healthy adult blood
were obtained from the literature with the Human Metabolome
Database (www.hmdb.ca) (36), most of which more closely re-
sembled concentrations in CMM than those in HMI11 (Table 2).
Comparative phenotypic analysis of trypanosomes grown in
CMM or HMI11. Comparison of growth curves and gross mor-
phology revealed no significant phenotypic differences between
cells cultured in CMM and those cultured in HMI11 (Fig. 2). To
determine cryptic changes in composition, however, a detailed
LC-MS metabolomic analysis of intracellular metabolism was
performed to investigate the impact of medium composition on
cellular metabolism.
Untargeted metabolomic analysis with the formic acid ZIC-
HILIC–Orbitrap platform putatively identified 522 metabolites in
cultured bloodstream form T. brucei. Semiquantitative analysis
with uniformly 13C-labeled E. coli extract for normalization re-
vealed that 74% of the metabolites were not affected by the culture
medium, showing no significant difference in metabolite abun-
FIG 1 Relative changes in concentrations of nutrients in spent medium following 56 h of cell growth (to 4  106 cells ml1). (A) Relative changes in the
concentrations of targeted metabolites in HMI11 (filled columns) and CMM (open columns). The pyruvate concentration in CMM increased 10,000-fold,
from below the limit of detection (1M) to 12 mM. (B) Changes in the relative abundance of all putative metabolites in HMI11. Lipids (blue squares) are mostly
unchanged, with the exception of LPCs (LysoPC; larger blue filled squares); many peptides (green triangles) are slightly depleted; and most other classes of
putative metabolites (red circles) are unchanged, with the notable exception of the amino acid-derived keto acids (larger red filled circles) and the purine
nucleosides inosine and guanosine (filled purple diamonds).
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dance at any of the cell densities tested (P 0.05), and only 6% of
the metabolites demonstrated 3-fold differences across all cell
densities (Fig. 3A).
Many of the metabolites that were less abundant in CMM-
grown cells can be explained by direct uptake of the excess nutri-
ents in HMI11 (Fig. 3B), and the lower concentrations of many of
these metabolites observed in CMM are closer to physiological
concentrations in the parasite’s natural habitat, blood. Interest-
ingly, the intracellular concentrations of 11 HMI11 nutrients were
not significantly different, even though these nutrients were ex-
cluded from the CMM recipe and present at much lower concen-
trations than in HMI11 medium (Fig. 3C), indicating intrinsic
mechanisms of homeostasis of these metabolites in the parasites.
Some metabolites were more abundant in cells grown in CMM
than in cells grown in HMI11, indicating localized changes in
cellular metabolism. These included ornithine, variously acety-
lated and methylated amino acids, and metabolites related to cys-
teine and methionine (Fig. 3D).
Analysis of cellular metabolism as the cell density increased
from 2 106 to 4 106 cells ml1 revealed significant changes in
the concentrations of one-fifth of the putatively identified metab-
olites in both CMM (20%) and HMI11 (18%) (for details, see the
IDEOM file in the supplemental material). Intracellular pyruvate
increased 2-fold (because of the major role of glycolysis in energy
generation). Interestingly, intracellular glutamate levels were de-
pleted by50% in HMI11-grown cells, despite no decrease in the
730 M concentration of glutamate in the medium. The same
trend was observed for CMM-grown cells, demonstrating sub-
stantial metabolic alterations as the cell density increased toward
stationary phase, regardless of the growth medium and without
any external intervention.
Drug testing with CMM. The performance of CMM in drug
sensitivity testing was evaluated by standard alamarBlue assay of
16 clinically used and experimental trypanocides. In most cases,
the IC50s obtained in CMM were comparable to those obtained in
HMI11. Six compounds showed no significant effect of the me-
dium on the IC50, and the differences observed with seven other
compounds were 3-fold in magnitude (Fig. 4). Interestingly,
three of the compounds tested exhibited 100-fold increases in
activity in CMM over that in HMI11. Pentamidine, already the
most potent of the trypanocides evaluated in HMI11 (IC50 1.2
nM), was remarkably more active in CMM (IC50  0.003 nM).
Methotrexate, a relatively poorly active compound in HMI11
(IC50 4.6M), demonstrated good activity in CMM (IC50 10
nM). Likewise, pemetrexed was barely active in HMI11 (IC50 50
M) but highly active in CMM (IC50 18 nM). Methotrexate and
pemetrexed are both known to inhibit DHFR, resulting in inhibi-
tion of folate metabolism and subsequent biosynthesis of thymi-
dine nucleotides (37). Hence, the lower activity observed in
HMI11 is likely due to rescue by the high concentrations of folate
in HMI11 medium compared to CMM. To confirm this, CMM
was prepared with additional folate at the same concentration as
that found in HMI11. Methotrexate activity in folate-supple-
mented CMM was reduced150-fold to 1,500 nM but not com-
FIG 2 Growth curves of T. brucei cultures grown in nutrient-depleted medium. (A) Equivalent growth observed for HMI11 (diamonds) compared to diluted
HMI11 without vitamins (Dil-Vit; triangles) or diluted HMI11 without amino acids and nucleotide precursors (Dil-AA/N; squares). (B) Equivalent growth
observed in HMI11 (triangles), basal medium with cysteine with glutamine (CQ; squares), or cysteine with phenylalanine and tryptophan (CFW; diamonds) but
not in glutamine with phenylalanine and tryptophan (QFW; crosses). (C) Equivalent growth observed in HMI11 and CMM. (D) Short-term growth curves
obtained with HMI11 and CMM showing a maximal cell density of around 5 106 cells ml1 and subsequent cell death.
Creek et al.
2772 aac.asm.org Antimicrobial Agents and Chemotherapy
pletely diminished to the IC50 obtained in HMI11. Additional
studies with thymidine-supplemented CMM showed a 4-fold re-
duction in activity compared to that in CMM, and the combina-
tion of CMM with folate and thymidine resulted in methotrexate
activity (IC50) equivalent to that in HMI11 (Fig. 4B).
The reason for the major increase in pentamidine activity in
CMM is unclear, as the mechanism of action of pentamidine re-
mains under debate. The other diamidines tested in this study,
diminazene and DB75, showed much smaller increases in activity
in CMM than in HMI11 (3.0- and 2.4-fold, respectively). The
larger differential observed for pentamidine in these two media
suggests a difference in the mechanism of action and/or uptake of
pentamidine versus diminazene and DB75. Since it is already
known that pentamidine’s uptake is more dependent on the
HAPT1 and LAPT1 transporters than that of either DB75 (38) or
diminazene (39) is, it is not surprising to identify such differences
in behavior.
Pentamidine induced changes in the T. bruceimetabolome.
In order to further elucidate the mechanism of action of pentam-
idine, a metabolomic approach was applied to cell cultures with
both HMI11 and CMM. Previous work indicated how this ap-
proach can be useful in identifying a drug’s mode of action when
increases in the ornithine concentration and decreases in the pu-
trescine concentration were observed following the treatment of
T. brucei with eflornithine (15). In order to determine suitable
doses of pentamidine, growth curves were obtained at the higher
cell density (2  106 cells ml1) necessary to obtain suitable cell
numbers for metabolomic analysis. Under these conditions, a de-
layed-death phenotype was observed, whereby no effect on para-
site growth was observed within the first 24 h, as previously re-
TABLE 2 Absolute quantification of HMI components in fresh and spent media after 56 h of trypanosome growth to 4 106 cells ml1f
Component
Exptl concn (M)a Theoretical concn (M)
HMI CMM
HMI11
reciped
CMM
recipe
Human
bloode
Human
CSFeFresh Spent Fresh Spent
D-Glucosea 25,000 10,000 4,817 3,357
L-Cysteinea 3,349,188 1,426,490 661,446 147,585 3,987,853 435,789 254,831 85,829 1,504 1,000 99 0
L-Glutamine 4,002 238 3,382 191 727 11 289 6 3,998 1,000 550 490
L-Phenylalanine 327 16 224 8 76 1 1.3 0.1 400 79 11
L-Tryptophan 87 5 73 3 21 1 0.4 0.1 78 54 6
L-Tyrosine 1,013 60 951 44 194 5 115 6 574 89 11
L-Methionine 195 8 188 7 39 1 22 1 201 29 4
L-Arginine 692 40 715 28 225 1 219 9 482 110 21
L-Leucinea,b 48,270,601 13,204,959 44,388,168 4,445,117 17,478,123 2,079,608 4,996,443 584,426 801 158 14
L-Isoleucinea,b 801 69 7
L-Valine 440 30 517 69 385 22 404 44 803 234 19
L-Lysine 1,302 65 1,382 56 255 4 231 9 999 236 27
L-Threonine 899 52 895 42 102 2 72 4 798 155 31
L-Serine 553 33 555 27 193 7 156 10 400 145 30
L-Proline 483 60 572 57 128 5 115 5 348 190 3
L-Histidine 241 12 225 9 52 1 46 3 271 106 16
Glycine 482 25 542 25 179 4 183 9 400 266 8
L-Glutamate 729 39 791 32 179 3 216 10 510 76 13
L-Asparagine 276 13 284 10 91 1 88 4 189 50 7
L-Aspartate 338 19 367 15 100 2 103 6 226 21 2
L-Alanine 514 41 1,263 59 256 6 793 34 281 448 32
L-Cystinea 33,127 57,378 LODc 152,042 14,351 LODc 379 101 0.2
Pyruvate 937 17 9,408 503 4.7 1.2 11,525 2,053 1,295 60 98
Hypoxanthine 965 47 983 37 4.4 0.1 3.8 0.2 1,000 8 4
Thymidinea 154,748 29,103 507,275 74,464 LODc LODc 161 0.2
myo-Inositola 40 24 138
Cholinea 7,999,054 1,371,732 8,557,781 1,051,370 3,691,885 172,624 3,698,509 306,766 38 9 6
Nicotinamide 4 0.7 8.9 1.0 0.02 0.001 0.04 0.01 33 0.4
Pyridoxala 420,434 155,128 460,607 178,818 LODc 2,726 506 24 0.3
Pantothenate 26 2 29 2 2.0 0.1 1.8 0.1 18 4 3
Thiaminea 3,643,586 61,195 3,665,175 218,103 3,531,013 41,082 3,369,323 26,130 15 0.1 0.07
Folic acida 150,002 37,145 170,635 65,126 LODc LODc 9 0.03 0.02
Riboflavina 55,730 9,975 54,715 4,636 LODc LODc 1 0.3 0.4
Biotina 10,264 1,217 11,764 1,234 9,819 1,057 10,539 735 0.053 0.002 0.0005
Cyanocobalamina 0.010 0.0003 0.00002
a Absolute quantification of these metabolites could not be performed by the LC-MS methods and internal standards that were used in this study. Where possible, normalized peak
intensities (arbitrary units) are shown in italics to allow comparison of experimental relative abundances.
b Leucine and isoleucine peaks overlapped. Peak intensity represents the sum of both metabolites.
c A peak was not detected or was below the limit of detection (LOD), which was set at 1,000 arbitrary units.
d Theoretical concentrations of HMI11 components were taken from http://tryps.rockefeller.edu/trypsru2_culture_media_compositions.html.
e Theoretical concentrations in human blood and cerebrospinal fluid (CSF) are average values for healthy adults obtained from www.hmdb.ca.
f n 5.
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ported for diamidines (40). In HMI11, 5 nM pentamidine was
selected as the optimal dose to achieve an approximately 20%
reduction in parasite density at 48 h compared to that of untreated
cells. In CMM, the same effect was obtained with 0.5 nM pentam-
idine, in general agreement with a greater potency observed in
alamarBlue assays. Higher doses mediated50% cell death, mak-
ing it impractical to obtain suitable numbers of intact cells for
metabolomic analysis. Drug concentrations were significantly
higher than the IC50s obtained by alamarBlue assay, likely because
of the higher parasite density required for metabolomic studies
and the fact that the alamarBlue readout occurs at 72 h. Further
variability, albeit minor, was observed when samples were scaled
up to the full volumes required for the metabolomic experiments.
Pentamidine at 5 nM in HMI11 mediated approximately 50% cell
death after 48 h, whereas minimal trypanocidal activity was ob-
served in 0.5 nM pentamidine in CMM, thus providing data for
both lethal and sublethal doses of pentamidine (see the supple-
mental material).
Since intracellular metabolite concentrations are dependent
on cell density (Fig. 3) and cell density is decreased by drug treat-
ment, we were obliged to develop a novel sampling methodology
to ensure that all cultures were sampled at the same cell density
(see the supplemental material). This approach requires sampling
at different times; therefore, two untreated controls were included
to allow for potential time-dependent metabolic fluctuations, one
starting at the same cell density as treated cultures but sampled
earlier and a second starting at a lower cell density and sampled at
48 h. The two control samples allowed for the inclusion of a com-
FIG 3 Comparison of the intracellular T. brucei metabolome in HMI11 versus CMM during the late log growth phase from 2 106 to 4 106 cells ml1. (A)
Heat map of all putatively identified metabolites (rows) obtained by hierarchical clustering analysis. Samples (columns) cluster according to the growth medium,
but most intracellular metabolite levels are unchanged. Heat map data are log transformed and mean scaled. Orange, increased abundance; blue, decreased
abundance; green, unchanged abundance. (B) Numerous HMI11 components accumulate to greater levels in HMI11-grown cells (filled columns) than in
CMM-grown cells (open columns). (C) Many metabolites were not significantly different between cells grown in the two media, including a number of HMI11
components that were absent from the CMM formula. As the cell density increased, an increase in pyruvate and a decrease in glutamate were observed in both
media. (D) Examples of putative metabolites with a higher relative abundance in CMM than in HMI11, showing changes in amino acid metabolism involving
methylation, acetylation, and sulfur or redox metabolism. y axes show mean normalized LC-MS peak heights relative to those of cells grown in HMI11 at 2 106
cells ml1. Error bars represent standard deviations. Five biological replicates of each cell density, i.e., 2 106 (blue columns), 3 106 (red columns), and 4
106 (green columns) cells ml1, were measured.
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pletely drug-free control and a control with drug added after
quenching, which is essential for the interpretation of drug (or
contaminant)-derived features in untargeted LC-MS data.
Analysis of intracellular metabolite levels after 0-, 1-, 12-, and
24-h incubations with pentamidine revealed no major (2-fold)
reproducible drug-induced changes in the metabolome (Fig. 5A).
The most significant change was a 44% decrease in a metabolite
putatively identified as 10-formyldihydrofolate at 24 h (Fig. 5B).
This metabolite was completely depleted from HMI11 (below the
limit of detection) at 48 h but not observed at any time point in
cells grown in CMM (below the limit of detection). This observa-
tion suggests that pentamidine may interfere with folate metabo-
lism. However, supplementing CMM with folate had no impact
on measured activity (IC50 0.005 nM; P 0.05), indicating that
folate metabolism is not the primary target of drug action.
Numerous metabolites were significantly depleted after 48 h of
incubation with pentamidine in HMI11, including nucleotides,
lipids, carbohydrates, and amino acid metabolites (Fig. 5A). Ap-
proximately 50% cell death was apparent under these conditions,
and it is therefore likely that these were nonspecific changes in
metabolism in response to cell death and metabolite leakage.
None of these changes were observed after 48 h with the sublethal
dose of pentamidine in CMM, with the exception of inosine. In
addition to inosine, the only significant changes in known metab-
olites in CMM-grown cells were decreased levels of phenylalanine
and tryptophan (Fig. 5B). Changes in these aromatic amino acids
were not observed in HMI11, most likely because of the buffer
provided by the elevated concentrations present in the growth
medium. Unlike eflornithine (15), the metabolic profiles observed
for pentamidine-treated cells in HMI11 and CMM indicate that
FIG 4 (A) Trypanocidal activities (IC50s) of standard trypanocidal compounds in HMI11 (filled columns) and CMM (open columns). Large increases in the
activities of methotrexate, pentamidine, and pemetrexed in CMM were observed. Increased sensitivities to diminazene, DB75, eflornithine, NA42, and acivicin
in CMM were statistically significant (P 0.05) but relatively minor (2- to 3-fold). (B) The trypanocidal activity of methotrexate (MTX) in CMM was partly
inhibited by thymidine (4-fold increase in IC50) and folic acid (150-fold), and activity equivalent to that in HMI11 was observed upon the readdition of both folic
acid and thymidine. The data shown are the means standard errors of three to nine biological replicates.
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this drug is unlikely to act through the inhibition of specific met-
abolic pathways. The lower potency of pentamidine in HMI11
than in CMM did not appear to be due to altered uptake or accu-
mulation of pentamidine within the cell. The pentamidine levels
in cells in HMI11 were approximately 10-fold higher than those in
cells in CMM, in agreement with the 10-fold difference in the
initial pentamidine concentrations (Fig. 5C).
DISCUSSION
Here, we present a rational methodology, based on the analysis of
metabolite utilization, for the development of cell culture media
for specific applications. In the field of drug development, an op-
timal culture medium is one that mimics the in vivo biological
environment as closely as possible while supporting a phenotype
that enables meaningful biological studies. In the case of blood-
stream form T. brucei, a fully defined medium is not practical and
calf serum is generally used to supply many of the nutrients that
this parasite salvages from its mammalian host. Attempts to stan-
dardize media with either dialyzed serum (41) or bovine serum
proteins (42) have required many additional nutrients, and the
formulation of new media has been a largely empirical and time-
consuming endeavor. The commonly used HMI11 formula suc-
FIG 5 Pentamidine-induced changes in the metabolome over a 48-h time course in CMM versus HMI11. (A) Heat map of changes in the abundance of all
putative metabolites relative to that in untreated controls (Ctrl) during the 48-h time course in HMI11 and CMM. Red, increased; blue, decreased; yellow,
unchanged. (B) Inosine decreased significantly after 48 h of treatment in both media. Decreases in phenylalanine and tryptophan could be observed only in
CMM. 10-Formyldihydrofolate was detected only in HMI-grown cells. (C) The relative levels of pentamidine were approximately 10-fold higher in HMI11 (blue
filled diamonds) than in CMM (red open squares), in agreement with the 10-fold higher dosage. y axes show raw LC-MS peak heights in arbitrary units. The data
are the means standard deviations of three (CMM) or four (HMI11) biological replicates.
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cessfully supports continuous T. brucei culture and is based on
Iscove’s medium, which contains all of the major nutrients re-
quired for energy generation and macromolecule synthesis (11).
However, the concentration of many components is significantly
higher than the normal concentrations found in human blood or
cerebrospinal fluid, the natural in vivo environment of the stage of
T. brucei responsible for clinical pathogenesis (Table 2).
The metabolomics-based approach described here allowed
rapid evaluation of the actual nutrient utilization under standard
cell culture conditions. The relative consumption and production
of 35 HMI11 components and hundreds of serum-derived nutri-
ents were measured in a single experiment. Most of the HMI11
components were not depleted during cell growth, allowing the
development of a simplified medium. Targeted metabolomic
analysis revealed that many essential nutrients are present in fresh
10% FCS at concentrations close to the average levels reported in
human blood, and these concentrations are sufficient to support
growth rates in cell culture equivalent to those in HMI11. It is well
established that bloodstream form T. brucei acquires energy ex-
clusively from glycolysis (33) and that cysteine and a reducing
agent are required to maintain a cell culture in the absence of
feeder cells (9, 11). In addition to glucose and cysteine, the only
other nutrient that was not supplied in sufficient quantity by 10%
FCS was glutamine. Interestingly, the glutamine in the CMM rec-
ipe could be replaced with the aromatic amino acids phenylala-
nine and tryptophan. The significant accumulation of amino acid-
derived keto acids in spent medium is in agreement with previous
observations of accumulation of hydrophobic keto acids in the
plasma and urine of infected rodents (43, 44). This suggests a
crucial role for hydrophobic amino acids in the provision of
amino groups, possibly for methionine recycling (45). However,
methionine depletion from the medium suggests that methionine
acquisition occurs by uptake from the medium to a significant
degree (46), while accumulation of the corresponding keto acid in
spent medium suggests that methionine itself is an amino donor
for as-yet-uncharacterized substrates. The significant accumula-
tion of alanine in the spent medium suggests that transamination
of pyruvate to alanine may be a primary role of amino acid-de-
rived nitrogen.
When FCS was replaced with dialyzed serum, CMM did not
support growth, confirming that some of the nutrients supplied
by FCS are essential for growth. One potential disadvantage of this
reliance on FCS is the risk of batch variability; hence, the formula
was developed with FCS Gold (PAA, Piscataway, NJ), which is a
standardized reconstituted serum, to avoid the risk of interbatch
variation.
Indeed, one tested batch of tetracycline-free serum (Biosera)
failed to support optimal growth with CMM and LC-MS analysis
revealed amino acid levels lower than those in FCS Gold (data not
shown). The addition of six amino acids (Tyr, Phe, Trp, Leu, Met,
and Arg) at 100 M returned the growth rates to normal.
The untargeted metabolomic approach allowed rapid analysis
of the serum components that are extensively consumed during in
vitro growth. Many small peptides were depleted from the me-
dium, suggesting an active mechanism for the salvage of amino
acids from peptides or proteins in the extracellular environment.
While these mechanisms may not be essential for growth in rich
culture medium or even in human blood, they may play an im-
portant role in nutrient-starved environments such as cerebrospi-
nal fluid in central nervous system stage infection or during the
insect stage of the parasite life cycle. Also of significance was the
depletion of LPCs. Extensive utilization of LPCs is in agreement
with the lipid salvage mechanisms previously described for blood-
stream form trypanosomes (47). So dramatic was their loss that we
investigated whether this might represent the growth-limiting de-
terminant of bloodstream form trypanosome growth in vitro.
However, addition of fresh LPCs did not extend growth. No
known metabolite was completely removed from the medium by
the time cells had ceased to proliferate, nor were novel metabolites
that might be toxic detected; hence, a simple solution to the rela-
tively poor growth capacity ofT. brucei bloodstream forms in vitro
has not been found. Purine salvage is essential in trypanosomatids
that lack purine biosynthesis pathways, which explains the ob-
served depletion of inosine and guanosine from the medium.
These results suggest a preference for the uptake of purine nucleo-
sides rather than free purine bases, as hypoxanthine levels were
not significantly depleted in either hypoxanthine-rich (HMI11) or
hypoxanthine-depleted (CMM) medium. Depletion of inosine
and guanosine as the cells reached stationary phase suggested that
a lack of purine nucleosides may be growth limiting, but addition
of inosine (100 M) to HMI11 was unable to support growth to
higher cell densities, and it is likely that other factors such as pH,
redox, or quorum-sensing mechanisms prevent growth beyond
5 106 cells ml1.
The benefits of CMM for metabolomic studies were demon-
strated by the study of pentamidine action. The decreased number
of LC-MS artifacts was exemplified by hypoxanthine, which had
56 peaks annotated as “related peaks” in HMI11 according to the
algorithm in mzMatch (48), compared to just 7 in CMM. Overall,
the number of detected peaks from cells grown in CMM was only
5% lower than that from cells grown in HMI11, confirming that
the overall compositions of cells from the two media are very
similar. The major benefit of CMM was the ability to detect
changes in metabolites that are usually abundant in the medium.
No changes in hydrophobic amino acids were observed in pent-
amidine-treated cells in HMI11, whereas the lower levels of phe-
nylalanine and tryptophan in CMM allowed the detection of sig-
nificant changes in the intracellular concentrations of these
metabolites.
In a recent study of eflornithine action, we demonstrated sig-
nificant changes in the concentrations of the substrate and prod-
uct of the target enzyme, ornithine decarboxylase, within hours of
treatment with either lethal or sublethal doses (15). In contrast, no
such changes were observed during the early stages of pentami-
dine treatment, suggesting that the trypanocidal activity of pent-
amidine is not mediated by the direct inhibition of a single en-
zyme. Major changes in metabolite levels were apparent only after
48 h and 50% cell death, where metabolites from multiple meta-
bolic pathways were perturbed. In contrast, few major changes
were observed after 48 h of sublethal pentamidine treatment in
CMM, except for decreased levels of inosine, phenylalanine, and
tryptophan. This work has identified those three metabolites as
important nutrients for cell growth, and depletion of those me-
tabolites suggests increased metabolic turnover in treated cells.
Previous studies have linked pentamidine’s action to the inhi-
bition of various enzymes, including S-adenosylmethionine de-
carboxylase (49). However, in agreement with other previous
work (50), no effect on polyamine abundance was observed fol-
lowing pentamidine treatment. An in vivo study linked pentami-
dine activity to the accumulation of arginine and lysine (50); how-
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ever, our results showed no effect on basic amino acids in either
HMI11 or CMM. Overall, the metabolomic data do not support a
metabolic mode of action of pentamidine, and this finding is sup-
ported by recently published RITseq data that did not find any
relationships between metabolic enzymes and resistance to pent-
amidine (51). Pentamidine is known to bind DNA, and it is likely
that the mode of action is related to interactions with nucleic acids
(52) or mitochondrial membrane activity (53). While a metabo-
lomic approach is generally not suitable for the investigation of
modes of action involving macromolecules, the drug-induced de-
pletion of inosine and 10-formyldihydrofolate indirectly supports
a link between nucleotide turnover and pentamidine activity.
CMM was successfully applied to the determination of in vitro
drug efficacy in trypanosomes by the standard alamarBlue assay.
While many of the drugs tested displayed comparable potencies in
both CMM and HMI11, there were large differences observed for
pentamidine and the antifolates. These differences imply that
components of standard HMI11 medium inhibit the action of
these drugs by inhibition of drug uptake and/or inhibition of ac-
tion by direct interaction with the target or by metabolite rescue.
The increased activity of antifolates in folate-depleted medium
has been reported previously in T. brucei (17), and the increased
IC50 observed when folate and thymidine were increased from
CMM to HMI11 concentrations confirms the inhibitory effect of
these metabolites on methotrexate activity. Antifolates demon-
strate poor activity in standard drug screening approaches with
rich medium, which might indicate that folate metabolism would
be an unsuitable drug target in trypanosomatids. Nevertheless,
DHFR has recently been confirmed as a validated drug target in T.
brucei, and it is suggested that HMI medium is unsuitable for
phenotypic drug screening of antifolates (17). This phenomenon
is likely to span many areas of metabolism, and it is likely that
high-throughput screening approaches using HMI11 have under-
estimated the potency of many trypanocidal compounds, partic-
ularly those that act by metabolic inhibition or rely on uptake by
metabolite transporters. CMM allows the screening of trypano-
cidal activity by established methods but in a medium that more
closely represents metabolite concentrations in human blood
(Table 2). This should allow the identification of novel com-
pounds with trypanocidal activity that might have otherwise gone
unnoticed if they were subject to inhibition by the high concen-
trations of nutrients in standard HMI11.
In addition to the improved sensitivity of drug activity testing
in CMM, the exclusion of 35 additives from HMI11 substantially
decreases the cost associated with regular trypanosome culture.
The physicochemical properties of all of the components allow the
rapid preparation of large volumes, and unlike those of HMI11, all
of the components dissolve rapidly (within minutes). The only
practical precautions, as with HMI11, are that 2-mercaptoethanol
should be added under a fume hood and the usual care should be
taken during pH adjustment.
In summary, this study has demonstrated that metabolomics is
a useful tool for the rational optimization of cell culture medium.
Furthermore, it offers a rapid and unbiased method for the anal-
ysis of cellular metabolism in different culture media. The mini-
mal medium (CMM) developed by this approach supports opti-
mal in vitro growth while providing a more biologically relevant
culture medium for experimental studies of T. brucei biology. In
particular, improved sensitivity has been demonstrated for com-
pound activity screening, which should substantially improve
drug discovery efforts for HAT treatment.
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